With a vision to develop intelligent diabetes management systems, French pharmaceutical company, Sanofi SA has partnered with Verily Life Sciences to form a new joint venture company named Onduo in Kendall Square in Cambridge, with an investment of approximately $500m.
The new company will combine Sanofi's clinical expertise and experience and Verily's knowledge in miniaturised electronics, analytics, and consumer software development to develop new and innovative treatment options for Type-2 diabetics.
It will focus on Type-1 diabetics and eventually on people who are at risk of developing diabetes.
Diagnostic and surgical medical components developer, Terumo Cardiovascular Group, has received exclusive rights from CytoSorbents Corporation to commercialise the latter's extracorporeal blood purification adsorber, CytoSorb, in six European countries, France, Sweden, Denmark, Norway, Finland, and Iceland.
The collaboration enables Terumo to offer its customers in European countries the innovative and easy-to-use blood purification therapy, which reduces excessive levels of inflammatory mediators in cardiac surgery patients.
To raise gross proceeds of $150m, Agios Pharmaceuticals has offered underwritten public offering of its common stock shares along with a 30-day option for the underwriters to buy an additional $22.5m shares.
The proceeds from the offering will be used by the company for the development and pre-commercialisation of its products AG-120 and AG-221 and for other working capital and generate corporate purposes.
Healthcare technology company, WellDoc, has joined hands with LifeScan, a Johnson & Johnson Diabetes Care Company (JJDCC), to develop a comprehensive digital therapeutic solution for Type 2 diabetes management.
The companies have entered a commercial partnership agreement, pursuant to which, WellDoc’s BlueStar diabetes management platform will be integrated with LifeScan’s OneTouch Verio Flex blood glucose monitoring system and the OneTouch Reveal digital system to provide a best-in-class diabetes management solution to those suffering from Type-2 diabetes.
Biolase, a dental laser and imaging systems provider, has announced a clinical research agreement with The McGuire Institute, a dental research organisation based in Richmond, Virginia, US.
Pursuant to the agreement, McGuire will initiate a landmark laser periodontal research project, which involves an independent, multi-centre, blinded research study on Biolase laser technology.
The study will compare the benefits of the technology with the traditional techniques used in managing periodontal disease.
Image: Sanofi and Verily have formed a joint venture to develop comprehensive diabetes management platform. Photo: courtesy of Sanofi.